LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model

Ken S. Rosenthal,1,2 Sarah Stone,2 Gary Koski,3 and Daniel H. Zimmerman4

1College of Medicine, Roseman University of Health Sciences, 10530 Discovery Drive, Las Vegas, NV 89135, USA
2Northeast Ohio Medical University, Rootstown, OH 44272, USA
3Kent State University, Kent, OH 44240, USA
4CEL-SCI Corporation, 8229 Boone Blvd, Suite 802, Vienna, VA 22182, USA

Correspondence should be addressed to Ken S. Rosenthal; krosenthal@roseman.edu

Received 21 November 2016; Revised 31 January 2017; Accepted 26 February 2017; Published 26 March 2017

Academic Editor: Bettahi Ilham

Copyright © 2017 Ken S. Rosenthal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The prototype J-LEAPS T cell vaccine for HER-2/neu breast cancer (J-HER) consists of the murine HER-2/neu66-74 H-2d CD8 T cell epitope covalently attached through a triglycine linker to the J-immune cell binding ligand (ICBL) (human β2 microglobulin38-50 peptide). The J-ICBL was chosen for its potential to promote Th1/Tc1 responses. In this proof-of-concept study, the ability of J-HER to prevent or treat cancer was tested in the TUBO cell-challenged BALB/c mouse model for HER-2/neu-expressing tumors. The J-HER vaccine was administered as an emulsion in Montanide ISA-51 without the need for a more potent adjuvant. When administered as a prophylactic vaccination before tumor challenge, J-HER protected against tumor development for at least 48 days. Despite eliciting protection, antibody production in J-HER-immunized, TUBO-challenged mice was less than that in unimmunized mice. More importantly, therapeutic administration of J-HER one week after challenge with TUBO breast cancer cells limited the spread of the tumors and the morbidity and the mortality in the challenged mice. The ability to elicit responses that prevent spread of the TUBO tumor by J-HER suggests its utility as a neoimmunoadjuvant therapy to surgery. Individual or mixtures of J-LEAPS vaccines can be readily prepared to include different CD8 T cell epitopes to optimize tumor therapy and customize treatment for individuals with different HLA types.

1. Introduction

CD8 T cells optimized for antitumor activity are initiated by interleukin 12- (IL12-) producing dendritic cells (DC1) presenting peptide epitopes from tumor proteins on MHC I antigens [1]. IL12 promotes production of CD4 T cells (Th1) and CD8 T cells (Tc1) which produce interferon γ (IFNγ) [1–4] and promotes the production of CD8 cytotoxic T cells (CTL) that are more sensitive to antigen than T cells induced by other responses [1, 5–7]. Th1/Tc1 responses are important for generating antitumor protections [1, 4], and IL12 also promotes other supportive antitumor activities [8].

The Ligand Epitope Antigen Presentation System (LEAPS) technology converts a small peptide containing a disease-specific epitope into an immunogen while simultaneously directing the nature of the subsequent immune response by covalently attaching the peptide to an immune cell binding ligand (ICBL) through a triglycine linker [9]. The J-ICBL is a peptide from the beta-2-microglobulin component of MHC I ((aa38–50) (DLLKNGERIEKVE) [10]) and promotes Th1/Tc1-type responses [11–16] to MHC I-binding peptides as small as a minimal CD8 T cell epitope of 8 amino acids. The G- or derG-ICBL is a peptide from the beta chain of human MHC II ((aa135–149) (DGQEEKAGVVSTGLI)) and promotes Th2-type responses [11, 17].

J-LEAPS vaccines have elicited immune responses to Mycobacteria tuberculosis antigens [11] and HIV [18],
initiated antimicrobial prophylaxis to HSV-1 [12–15] and influenza [16], and provided an immunomodulating influence on ongoing autoimmune responses [19–21], as demonstrated in appropriate mouse models. Protection from lethal challenge with HSV-1 followed immunization with JH1 [14], an 8-amino acid CD8 T cell epitope from the HSV-1 ICP27 protein whereas the component peptides elicited no protection. An antibody to this intracellular protein was not produced and would not have been protective [22]. Immunization with a conjugate containing a longer peptide from HSV-1 glycoprotein D, JgD, elicited protection from disease and death that was dependent upon IFNγ, CD8, and CD4 cells, as indicated by ablation studies, but only generated a Th1/Tc1-associated antibody response (IgG2a/IgG1 > 1) in those mice with minor breakthrough disease [15]. The GgD vaccine elicited Th2-associated antibody responses, but neither the GH1 [14] nor the GgD [15] vaccines elicited protections in the HSV-1-challenge models. J-LEAPS vaccines activate and direct the nature of the subsequent immune response to a Th1/Tc1 response by promoting the maturation of mouse and human precursor cells into IL12-producing dendritic cells (DC1s) which also present the antigenic peptide in the conjugate to CD8 T cells [12, 13, 16]. Based on these previous findings, we hypothesized that a hetero-conjugate vaccine combining the LEAPS J-ICBL with a CD8 T cell epitope from breast cancer cells would elicit potent antitumor responses.

Cells from breast cancer and a variety of other human malignancies express the HER-2/neu cell surface receptor and are dependent upon its function [23]. Peptides from HER-2/neu are presented on MHC I as antigens that can be recognized by CD8 T cells, and several of the peptides have been tested as antitumor vaccines in mouse models [24] and considered for humans [25]. The peptide vaccines administered with incomplete Freund’s adjuvant (IFA) are ineffective but, when administered with powerful adjuvants such as a toll-like receptor agonist, elicit antitumor CD8 T cell responses [24].

In this proof-of-concept study, a LEAPS vaccine for HER-2/neu-positive breast cancer was prepared by covalent attachment of the J-ICBL using a triglycine spacer to a prominent CTL-eliciting minimal CD8 T cell epitope from HER-2/neu (aa66-74: TYVPANASL) for BALB/c mice (J-HER) [24]. The vaccine, administered as an emulsion with an IFA-like Montanide ISA-51 oil in water emulsion adjuvant, was tested for its ability to elicit prophylactic and therapeutic responses in mice challenged with TUBO cells. TUBO cells [26] were originally obtained from a spontaneous mammary gland tumor that arose in a BALB-neuT mouse and generate HER-2/neu-expressing tumors.

2. Materials and Methods

2.1. Vaccine. J-HER peptide (DLLKNGERIEKVE-GGG-TYVPANASL, mwt 2631) was synthesized by FMOC chemistry, purified ≥95% by RP-HPLC, mass-determined by MS to ±2.4 atom, lyophilized by 21st Century Biochemicals, Marlboro, MA, and supplied as an acetate salt. The peptide was resuspended in sterile Hank’s balanced salt solution (HBSS) to 2 mM after checking pH and adjusting if necessary to 7.4. Prior to immunization, a 1:1 emulsion of J-HER was prepared in Montanide ISA-51 (SEPPIC Inc., Fairfield, New Jersey) adjuvant.

2.2. TUBO Cell Tissue Culture. TUBO cells [26] were kind gifts of Dr. Guido Forni (University of Turin). The cells were grown in tissue culture in RPMI 1640 medium supplemented with 10% fetal bovine serum (HyClone), penicillin (100 IU/mL), streptomycin (100 g/mL), and 2.25 mM NaHCO3 at 37°C. TUBO cells were demonstrated to be free of mycoplasma and contaminating viral infections and were limited to low passage for implantation in BALB/c female mice (Jackson Laboratories, Bar Harbor, ME). Mice were 7–10 weeks old when implanted with TUBO cells.

2.3. Tumor Challenge. TUBO cells were injected subcutaneously in a 50–100 μL volume into two parallel sites on the abdomen. A tumor cell amount of 2.5 × 105 per site was determined to be a lethal challenge. Mice were examined every other day. Tumor volume was determined by measuring along the longest axis of the tumor, along the second line perpendicular to this axis, and along the height and are presented as an average for the survivors of the group. Mice were also evaluated for other visible signs indicating poor health, including poor hygiene, lethargy, coat matting, ulceration, wasting and belly swelling due to ascites, inability to reach food and water, or excessive tumor size (>50% body mass). When necessary, mice were euthanized with carbon dioxide.

All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Northeast Ohio Medical University.

2.4. Prophylaxis Challenge Model. Mice were immunized in three locations, bilaterally into the abdomen at 40 μL per site followed by a 20 μL injection into the dorsal nape of the neck with an emulsion of HBSS as the control (n = 14) or J-HER peptide ((DLLKNGERIEKVE-GGG-TYVPANASL) in HBSS (1 mM (0.26 mg total peptide per immunization)) (n = 7) in Montanide ISA-51 adjuvant. Immunizations were at 3 weeks and 1 week prior to challenge. TUBO cell challenge was administered by subcutaneous implantation of 2.5 × 105 cells into a site on either side of the lower abdomen.

2.5. Therapeutic Challenge Model. Tumor development was initiated by subcutaneous injection of TUBO cells into two sites (2.5 × 105 cells per site) in mice. Mice were treated with the J-HER vaccine (n = 9) or the control (n = 9), as described for the prophylaxis trial, one week after initiation of the challenge and repeated every two weeks after the initial treatment. In addition to tumor volume and mortality, a disease score for each mouse was calculated by the following formula: tumor load (1–3 points), presence of skin necrosis at the site of the tumor (+1 point), ascites (+1 point), general unemptiness/healthy appearance (+1 point), and death (+4 points); and presented as an average for the group.
Figure 1: J-HER prevention of TUBO cell tumor development. Mice were immunized with HBSS in Montanide ISA-51 adjuvant (orange rectangles) or J-HER in adjuvant (green circles), which was repeated 14 days later, and one week later, immunized mice (n = 7) and unimmunized mice (n = 14) were challenged with 2.5 × 10^7 TUBO cells in each of two sites. Tumor volume is presented with respect to day after tumor challenge. Inset shows total tumor size for individual mice at day 48, end of experiment. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.)

3. Results

3.1. J-HER Immunization to Prevent Tumor Development. Mice were immunized with an emulsion of HBSS or J-HER peptide (DLLKNGERIEKVE-GGG-TYVPANASL) (2 mM) in Montanide ISA-51 adjuvant (100 microliters per mouse) at 3 weeks and 1 week prior to challenge with subcutaneous implantation of 2.5 × 10^5 TUBO cells into two sites on either side of the lower abdomen. J-HER includes a minimal MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu (peptide p66-74, TYVPANASL) covalently attached to the J-ICBL through a triglycine linkage.

Unimmunized mice developed measureable tumors within 14 days after injection of TUBO cells into the abdomen (Figure 1). Although the TUBO cells were injected subcutaneously, tumor growth extended into the abdomen and through the skin (Figure 2). In addition to the tumor swelling at the two implantation sites, the control mice had ruffled fur on the abdomen and exhibited poor hygiene, lethargy, and matted coats. Necropsy of representative animals showed multiple nodules within the mesentery of the abdomen with visible vascularization of the nodules (see Figure 2). In contrast, for the J-HER-immunized mice, there was minimal evidence of tumor development or disease signs over the course of the trial, 48 days after injection of TUBO cells. The bellies of the J-HER-vaccinated mice were flat, the fur was smooth, and on necropsy, vaccinated mice did not show the presence of tumors.

Serum was obtained from mice on day 7 after tumor challenge (28 days after the first immunization) and evaluated for HER-2-neu-specific antibody by ELISA (Figure 3). Interestingly, J-HER-vaccinated and TUBO-challenged mice had lower antibody titers to HER-2-neu than unvaccinated and TUBO-challenged mice. This is consistent with the lack or limited antibody generation by J-ICBL-based LEAPS vaccines [11, 14].

2.6. ELISA for IgG Antibody to HER-2/neu. Sera were obtained following blood collection after a lancet puncture of the submandibular vein (lancets from Goldenrod, 4 mm). Blood was permitted to clot at room temperature for 2–3 hours and then an additional 2–3 hours at 4°C, centrifuged to separate clot from serum and serum withdrawn, and placed in labeled storage vials. Sera were frozen until analysis.

ELISA was used to test for the presence of IgG antibody reactive to the extracellular domain (ECD) of recombinant HER-2/neu. EIA/RIA plates were coated with 50 μL of a recombinant HER-2/neu ECD (ACROBiosystems, Newark, DE) at a concentration of 5 μg/mL in 0.15 M sodium carbonate bicarbonate buffer pH 9.6 and incubated overnight at 4°C. The plates were then washed three times with PBS/Tween (0.05%) and then blocked with 200 μL of 1% bovine serum albumin (BSA) in PBS/Tween for 1 hour. The plates were washed again three times using the same wash buffer, and 50 μL of sera was added at a dilution of 1:10 or 1:100 in 1% BSA. The plates were incubated at room temperature for 2 hours, then washed three times. The presence of bound HER-2 antibodies in each well was detected by adding 50 μL of antimouse IgG secondary antibody conjugated to HRP (Thermo Scientific) for 1 hour, washing three times, developing the plate with 50 μL/well of TMB (3,3′,5,5′-tetramethylbenzidine) substrate (KPL, Kirkegaard & Perry Laboratories Inc., Rockville, MD), stopping the reaction with 25 μL/well of 1 N HCl, and reading the optical density of the resulting reaction at 450 nm.

2.7. Statistics. GraphPad Prism 6 Software (GraphPad, La Jolla, CA) was used to plot the data and also for recalculation of statistics. The two-way ANOVA Fisher LSD test was applied at 95% confidence interval to determine the statistical significance between the groups. A value of p < 0.05 is considered significant.
3.2. **J-HER Immunization to Treat Established Tumor Progression.** Mice were treated with the J-HER vaccine one week after initiation of tumor development by subcutaneous injection of TUBO cells into two sites ($2.5 \times 10^5$ cells per site). Vaccine treatments were repeated every two weeks after the initial treatment.

Unlike the untreated mice, J-HER-treated mice appeared otherwise healthy and tumor morbidity and mortality were significantly reduced (Figure 4). Mice treated with J-HER showed a lag in the development of tumors compared to untreated mice but still developed tumors (Figures 4(a) and 4(b)). The Kaplan-Meier depiction of survival clearly shows the benefits of J-HER treatment (Figure 4(c)). Mortality was delayed and more mice survived compared to untreated mice.

Since tumor load was only one indicator of the differences between untreated and J-HER-treated tumor-bearing
animals, an alternative means of evaluation was developed to generate a total disease score of up to ten points based on the following: tumor load (0–3), presence of skin necrosis at the site of the tumor (+1), ascites (+1), general unkempt/unhealthy appearance (+1), and death (+4) (Figure 4(d)). The disease score at death was carried through for all subsequent days and calculations. Using this disease score, deviation of the outcomes became apparent 35 days after TUBO cell challenge coincident with the second immunization. The higher scores of the untreated mice represented the unkempt/unhealthy appearance of the mice (poor hygiene, lethargy, coat matting, ulceration, and wasting) and the greater number of deaths of untreated mice.

The difference in mouse health can be seen in the pictures taken at necropsy on day 57 (Figure 5). Whereas untreated mice showed multiple tumor nodules spread throughout the abdomen, J-HER-treated mice showed a single tumor or limited tumor growth at the sites of the initial TUBO cell injection. The tumors did neither invade the abdomen nor spread and did not break through the skin and fur, as occurred for the untreated mice. This clearly shows that the J-HER treatment prevented the morbidity, mortality, and spread of tumors that occurred in the untreated mice.

4. Discussion

This pilot project demonstrated that the immune response elicited by J-HER was sufficient to prevent the initial development of tumor outgrowth in the TUBO breast cancer tumor model when administered prior to challenge. Presentation of J-LEAPS vaccines in an oil in water emulsion provides a reservoir for slow release is important for efficacy [14, 15] and why J-HER was administered in Montanide ISA-51. Others showed that strong adjuvants, such as TLR ligands, must be added to an oil in water emulsion (incomplete Freund’s adjuvant) in order to elicit protection by the HER epitope [24], but this was not necessary with the J-HER vaccine.

The J-HER treatment limited tumor spread and the associated morbidity of disease progression but was not capable of eliminating the tumors that were initiated and then grew during the time period prior to immunization (one week)

---

**Figure 4**: J-HER treatment of TUBO cell-challenged mice. Mice were challenged with $2.5 \times 10^7$ TUBO cells in each of two sites and then immunized with HBSS in Montanide ISA-51 adjuvant (control $n=9$) or J-HER in adjuvant (vaccine $n=9$) one week later and at two-week intervals thereafter. Data is presented with respect to day after tumor challenge. (a) The average tumor load by volume for untreated mice. Mice that died during the trial are indicated by values of 16,000 and mice with no tumors are indicated by a diamond. (b) The average tumor load by volume for J-HER-treated mice, depiction as for panel (a). (c) Kaplan-Meier plot of survival on days shown after tumor challenge. (d) The disease score (calculated as defined in the Methods). ($^* p < 0.05; ^{**} p < 0.01; ^{***} p < 0.001; ^{****} p < 0.0001.$)
Incorporation of three di
from HSV-1 into J-LEAPS vaccines elicited antigen-spe
vaccines in which attachment of the J-ICBL to CD8 T cell
J-LEAPS vaccine was indicated in studies with in
nogens. The requirement for a CD8 T cell epitope in the
G- or derG-LEAPS vaccine failed to yield protective immu-
activity. Incorporation of these epitopes into a similar-sized
did not elicit measureable responses and had no protective
(HSV-1) lethal challenge whereas the unconjugated peptides
provide protection in models with herpes simplex virus 1
Th1/Tc1-related immune responses that were su
1610 m³. (c) Treated, day 56, tumor size: 6780 m³, survived the trial. (d) Treated, day 57, tumor size: 6390 m³. Red arrows indicate tumors at the site of implantation. Green arrows represent nodular tumors that spread within the abdomen.

and required to elicit a sufficient immune response (~two
weeks) to the J-HER treatment. Control of the spread of the
tumors made a large difference in the health and survival of
the J-HER-treated mice. It is likely that the response elicited by J-HER was capable of eliminating individual
tumor cells when they arise, similar to the prevention trial, but was not able to enter or was insufficient to eliminate
an established tumor.

Despite elicitation of protection in the prevention model
and unlike most vaccines, the antibody response to the HER-
2/neu protein in J-HER-immunized mice was less than that
in unvaccinated mice. This suggests that antibody is not the
primary means of prevention elicited by the J-HER vaccine.
This is consistent with other J-LEAPS vaccines that elicit
protection from death and disease upon HSV-1 challenge
without detectable antibody production [9, 11, 14, 15].

Incorporating the HER-2/neu66–74 (HER) peptide into a
J-LEAPS vaccine was intended to enhance the immunogenic-
ity of the minimal MHC I epitope for CD8 T cells and direct
the nature of subsequent immune responses towards Th1/
Tc1. The HER peptide has limited immunogenicity due to its
small size, as observed by others when administered in
incomplete Freund’s adjuvant [24]. The J-HER vaccine was
designed based on previous findings for anti-HSV-1 vaccines
[9, 14, 15]. Incorporation of three different CTL epitopes
from HSV-1 into J-LEAPS vaccines elicited antigen-specific
Th1/Tc1-related immune responses that were sufficient to
provide protection in models with herpes simplex virus 1
(HSV-1) lethal challenge whereas the unconjugated peptides
did not elicit measureable responses and had no protective
activity. Incorporation of these epitopes into a similar-sized
G- or derG-LEAPS vaccine failed to yield protective immu-
nogens. The requirement for a CD8 T cell epitope in the
J-LEAPS vaccine was indicated in studies with influenza vaccines in which attachment of the J-ICBL to CD8 T cell
epitopes generated protective immunogens but attachment
to CD4 T cell/B cell epitopes did not [16]. As for the anti-
HSV-1 and anti-influenza vaccines, an effective vaccine
was generated by covalent linkage of an appropriate CD8
T cell epitope (HER) from HER-2/neu to the J-ICBL.

As for the JgD (HSV) and JH (HIV) vaccines, immuniza-
tion with J-HER is expected to promote the maturation of
dendritic cell precursors and elicit production of IL12 and
IFNy [9, 14, 15]. Immunization of mice with the JgD
anti-HSV vaccine without infection elicited IL12p70,
IL17, and IFNy serum responses in mice. Both the JgD
vaccine and JH vaccines promoted maturation of murine
bone marrow and human monocyte precursors to become
IL12-producing dendritic cells [14, 15], ex vivo. The human
JgD- and JH-induced DC1s elicited IFNy production in
mixed lymphocyte reactions [15], and murine JgD and
JH DC1s elicited IFNy production from T cells ex vivo.
Adoptive transfer of the HSV-1-specific JgD-induced DC1s
but not the HIV-specific JH-induced DC1s was sufficient to
elicit antigen-specific protection from lethal HSV-1 challenge
[14]. A J-HER-induced DC1 would also be expected to
promote the development of Th1/Tc1 cells, and CTLs with
greater sensitivity for MHC I presented tumor antigens [1–6].

The ability to limit potential metastatic spread or residual
breast cancer disease by this type of vaccine response would
be beneficial as a neoadjuvant therapy after surgical removal
of the bulk tumors. Using similar logic, Koski, Czerniecki,
and their collaborators demonstrated that HER-2/neu-loaded
DC1 cells injected into the draining lymph node were effec-
tive as neoadjuvant therapy for breast cancer [7, 27].
Similarly, the J-HER peptide vaccine would be expected to
promote maturation of DC1s, appropriate activation of
CD8 T cells, and a systemic response that could attack
individual metastatic tumor cells and prevent spread to
lymph nodes.

Figure 5: Appearance of representative mice from the J-HER treatment trial described in Figure 4. TUBO cell tumor development is shown for different control and J-HER-immunized mice. (a) Control, day 56, tumor size: 4775 m³, died on day 75. (b) Control, day 57, tumor size: 1610 m³. (c) Treated, day 56, tumor size: 6780 m³, survived the trial. (d) Treated, day 57, tumor size: 6390 m³. Red arrows indicate tumors at the site of implantation. Green arrows represent nodular tumors that spread within the abdomen.
With the demonstration that a J-HER immunization is effective for prevention and treatment in this proof of principle with the TUBO-challenge model, similar antitumor vaccines using alternative mouse or human CD8 T cell epitopes can be conceived. T cell-activating peptide vaccines can be customized for the tumor and the type of animal or for different individuals. Initial vaccine development would target antigens for the more common MHC molecules, such as HLA A2 [28]. The sequence of the relevant tumor antigen peptide can be predicted in silico or obtained from sequences reported in the literature. In addition to single-epitope vaccines, like J-HER, mixtures of J-LEAPS vaccines containing multiple epitopes from the same protein or different proteins can provide broader immune system coverage and minimize the chance of mutational escape by the tumor from immune surveillance. The CD8 T cell epitope targets can be optimized for the antitumor responses while excluding epitope targets associated with tolerance or autoimmunity conditions. As peptides, single peptide or mixtures of antitumor J-LEAPS vaccines can be customized and synthesized for humans of different MHC types.

Conflicts of Interest

K. S. Rosenthal is the coinventor on several patents on LEAPS technology but independent of CEL-SCI. Research on this project was performed independent of CEL-SCI. D. H. Zimmerman is an employee, officer, and stockholder of CEL-SCI Corp. and inventor and coinventor on multiple patents on LEAPS technology. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Acknowledgments

These studies were funded in part by an unrestricted grant from CEL-SCI Corporation. The authors would like to thank Steven Cress and Roy Carambula at CEL-SCI Corporation for their assistance.

References

[1] S. Xu, G. K. Koski, M. Faries et al., “Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism,” *Journal of Immunology*, vol. 171, no. 5, pp. 2251–2261, 2003.

[2] M. Croft, L. Carter, S. Swain, and R. Dutton, “Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles,” *The Journal of Experimental Medicine*, vol. 180, no. 5, pp. 1715–1728, 1994.

[3] S. Sad, R. Marcotte, and T. Mosmann, “Cytokine-induced differentiation of precursor mouse CD8 T cells into cytotoxic CD8 T cells secreting Th1 or Th2 cytokines,” *Immunity*, vol. 2, no. 3, pp. 271–279, 1995.

[4] R. A. Kemp and F. Ronchese, “Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity,” *Journal of Immunology*, vol. 167, no. 11, pp. 6497–6502, 2001.

[5] A. Vaccaro, S. N. Freedman, N. M. Chapmana, and J. C. D. Houtman, “Pretreatment of activated human CD8 T cells with IL-12 leads to enhanced TCR-induced signaling and cytokine production,” *Molecular Immunology*, vol. 81, pp. 1–15, 2017.

[6] S. Tugues, S. Burkhard, I. Ohs et al., “New insights into IL-12-mediated tumor suppression,” *Cell Death and Differentiation*, vol. 22, no. 2, pp. 237–246, 2015.

[7] G. K. Koski, U. Koldovsksy, S. Xu et al., “A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer,” *Journal of Immunotherapy*, vol. 35, no. 1, pp. 54–65, 2012.

[8] K. Boggio, E. Di Carlo, S. Rovero et al., “Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice,” *Cancer Research*, vol. 60, no. 2, pp. 359–364, 2000.

[9] K. S. Rosenthal, P. Taylor, and D. H. Zimmerman, “J-LEAPS peptide and LEAPS dendritic cell vaccines,” *Microbial Biotechnology*, vol. 5, no. 2, pp. 203–213, 2012.

[10] P. Parham, M. J. Androlewicz, N. J. Holmes, and B. E. Rothenberg, “Arginine 45 is a major part of the antigenic determinant of human â2-microglobulin recognized by mouse monoclonal antibody BBM1,” *The Journal of Biological Chemistry*, vol. 258, no. 10, pp. 6179–6186, 1983.

[11] D. Zimmerman, S. Morris, D. Rouse, K. Worthington, D. Elliott, and K. S. Rosenthal, “Immunoization with peptide heteroconjugates primes a TH1 associated antibody (IgG2a) response which recognizes the native epitope on the 38 kDa protein of mycobacterium tuberculosis,” *Vaccine Research*, vol. 5, no. 2, pp. 103–118, 1996.

[12] P. R. Taylor, G. K. Koski, C. C. Paustian et al., “J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells,” *Vaccine*, vol. 28, no. 34, pp. 5533–5542, 2010.

[13] P. R. Taylor, C. C. Paustian, G. K. Koski, D. H. Zimmerman, and K. S. Rosenthal, “Maturation of dendritic cell precursors into IL12 producing DCs by J-LEAPS immunogens,” *Cellular Immunology*, vol. 262, no. 1, pp. 1–5, 2010.

[14] K. S. Rosenthal, H. Mao, W. L. Horne, C. Wright, and D. Zimmerman, “Immunoization with a L.E.A.P.S. heteroconjugate vaccine containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex type 1,” *Vaccine*, vol. 17, no. 6, pp. 535–542, 1998.

[15] N. Goel, Q. Rong, D. Zimmerman, and K. S. Rosenthal, “A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection,” *Vaccine*, vol. 21, no. 27–30, pp. 4410–4420, 2003.

[16] K. Boonnak, L. Vogel, M. Orandle, D. Zimmerman, E. Talor, and K. Subbarao, “Antigen-activated dendritic cells ameliorate influenza A infections,” *The Journal of Clinical Investigation*, vol. 123, no. 7, pp. 2850–2861, 2013.

[17] D. H. Zimmerman, K. F. Bergmann, K. S. Rosenthal, and D. A. Elliott, “A new approach to T cell activation: natural and synthetic conjugates capable of activating T cells,” *Vaccine Research*, vol. 5, no. 2, pp. 91–102, 1996.

[18] D. H. Zimmerman, J. P. Lloyd, D. Heisey et al., “Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide
segments of human beta-2-microglobulin or MHC II beta chain,” *Vaccine*, vol. 19, no. 32, pp. 4750–4759, 2001.

[19] D. Cihakova, J. G. Barin, G. C. Baldeviano et al., “L.E.A.P.S heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart,” *International Immunopharmacology*, vol. 8, no. 5, pp. 624–623, 2008.

[20] D. H. Zimmerman, P. Taylor, A. Bendele et al., “CEL-2000: a therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model,” *International Immunopharmacology*, vol. 10, no. 4, pp. 412–421, 2010.

[21] K. S. Rosenthal, K. Mikecz, H. Steiner et al., “Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis,” *Expert Review of Vaccines*, vol. 14, no. 6, pp. 891–908, 2015.

[22] T. A. Banks, S. Nair, and B. T. Rouse, “Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus,” *Journal of Virology*, vol. 67, no. 1, pp. 613–616, 1993.

[23] M. C. Hung and Y. K. Lau, “Basic science of HER-2/neu: a review,” *Seminars in Oncology*, vol. 26, no. 4, Supplement 12, pp. 51–59, 1999.

[24] P. Nava-Parada, G. Forni, K. L. Knutson, L. R. Pease, and E. Celis, “Peptide vaccine given with a toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors,” *Cancer Research*, vol. 67, no. 3, pp. 1326–1334, 2007.

[25] C. N. Baxevanis, N. N. Sotiriadou, A. D. Gritzapis et al., “Immunogenic HER-2/neu peptides as tumor vaccines,” *Cancer Immunology, Immunotherapy*, vol. 55, no. 1, pp. 85–95, 2006.

[26] K. Boggio, G. Nicoletti, E. Di Carlo et al., “Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice,” *The Journal of Experimental Medicine*, vol. 188, no. 3, pp. 589–596, 1998.

[27] B. Czerniecki, G. Koski, U. Koldovsky et al., “Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion,” *Cancer Research*, vol. 67, no. 4, pp. 1842–1852, 2007.

[28] K. L. Knutson, K. Schiffman, M. A. Cheever, and M. L. Disis, “Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide results in short-lived peptide-specific immunity,” *Clinical Cancer Research*, vol. 8, no. 5, pp. 1014–1018, 2002.